Ketamine Depression Program Launches in Bangkok: Policy and Clinical Implications
The Mend’s new ketamine-assisted therapy program for depression in Bangkok marks a significant step for psychedelic treatment access in Southeast Asia, raising questions about regulatory oversight, clinical standards, and regional policy development.
The Mend Launches Ketamine Program for Depression in Bangkok
The Mend, a mental health provider, has announced the launch of a ketamine-assisted therapy program for depression in Bangkok, Thailand, as reported by Nation Thailand on November 16, 2026. This initiative represents one of the first publicized efforts to offer psychedelic-assisted therapy for mental health conditions in Southeast Asia, a region where such interventions have historically faced significant regulatory and cultural barriers. The program’s specifics, including its clinical model, patient eligibility criteria, and oversight mechanisms, have not yet been disclosed by The Mend.
Mechanism of Ketamine-Assisted Therapy and Clinical Context
Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has demonstrated rapid-acting antidepressant effects in multiple randomized controlled trials, primarily in North America and Europe. In clinical settings, ketamine is typically administered intravenously or intranasally under medical supervision, with patients monitored for dissociation, blood pressure changes, and other acute effects. The Mend’s program is expected to follow a similar protocol, though the absence of published details leaves open questions about dosing, session structure, and integration support. Notably, ketamine is the only psychedelic-class substance with a well-established off-label use for depression in many jurisdictions, but its long-term efficacy and safety profile remain under investigation.
Policy, Regulatory, and Research Implications for Southeast Asia
The introduction of ketamine-assisted therapy in Bangkok could serve as a catalyst for broader regulatory and policy discussions in Thailand and neighboring countries. Thailand’s Food and Drug Administration (Thai FDA) currently regulates ketamine as a controlled substance, but it is approved for medical use as an anesthetic. The regulatory pathway for its use in psychiatric indications, particularly in private clinics, is less clearly defined. The Mend’s entry into this space may prompt Thai regulators to clarify guidelines for psychedelic-assisted therapies, set standards for practitioner training, and require outcome reporting. This move could also encourage academic and clinical researchers in the region to initiate local trials, potentially generating Southeast Asia-specific data on ketamine’s efficacy and safety. A non-obvious implication is that early adopters like The Mend may influence not only clinical practice but also the framing of mental health stigma and the role of novel therapies in the region’s public discourse.
Risks, Unknowns, and Oversight Challenges
Launching a ketamine program for depression in a new jurisdiction carries significant risks and unknowns. The most immediate concerns are patient safety, quality assurance, and the potential for diversion or misuse of ketamine. Without transparent protocols and independent oversight, there is a risk that clinical standards may vary widely, potentially undermining patient trust and regulatory confidence. Additionally, the lack of published outcome data from The Mend’s program could limit the ability of clinicians and policymakers to assess its real-world impact. Another failure mode, often overlooked, is the risk of program discontinuity if regulatory scrutiny increases or if there is insufficient demand, potentially leaving patients without ongoing support. Regional differences in mental health infrastructure and cultural attitudes toward psychedelics may also affect uptake and outcomes.
Looking Ahead: Monitoring, Collaboration, and Data Sharing
The launch of The Mend’s ketamine program in Bangkok is likely to accelerate conversations about the role of psychedelic-assisted therapies in Southeast Asia. Stakeholders—including clinicians, researchers, regulators, and patient advocates—should monitor for regulatory responses, program outcomes, and opportunities for cross-border collaboration. Transparent data sharing from The Mend and similar programs will be critical to informing evidence-based policy and clinical practice. As the regional landscape evolves, proactive engagement with local health authorities and adherence to international best practices will be essential to ensuring both patient safety and the sustainable integration of psychedelic therapies into mainstream care.
Authored by Dr. Alex Charoensuk, MD, MPH. Reviewed by Dr. Napat Jirawat, PhD, on 2026-11-17. Research based on primary reporting from Nation Thailand and regulatory guidance from the Thai FDA.
Get tomorrow's briefing in your inbox
Policy, research, and regulatory signal — delivered on our publish cadence.